Last reviewed · How we verify
The suppression of graft-versus-host disease in hematopoietic stem cell transplantation
Approved treatments
- Cellcept · Roche Palo
Cellcept works by inhibiting the enzyme inosine-5'-monophosphate dehydrogenase 2, which is necessary for the production of guanosine nucleotides.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- The suppression of graft-versus-host disease in hematopoietic stem cell transplantation patent landscape — cliff calendar, originator estates, attackable patents
- The suppression of graft-versus-host disease in hematopoietic stem cell transplantation treatment landscape brief
- The suppression of graft-versus-host disease in hematopoietic stem cell transplantation treatment updates RSS
Frequently asked questions about The suppression of graft-versus-host disease in hematopoietic stem cell transplantation
What drugs treat The suppression of graft-versus-host disease in hematopoietic stem cell transplantation?
Tracked treatments include Cellcept.
What is the treatment for The suppression of graft-versus-host disease in hematopoietic stem cell transplantation?
Standard treatment for The suppression of graft-versus-host disease in hematopoietic stem cell transplantation includes Cellcept. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: The suppression of graft-versus-host disease in hematopoietic stem cell transplantation patent cliff · The suppression of graft-versus-host disease in hematopoietic stem cell transplantation CI report
- Treatment: Cellcept · Roche Palo
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing